ASP Isotopes outlines commercialization milestones and $300M EBITDA target
ASP Isotopes said at its inaugural Capital Markets Day in London that it is transitioning from development into early commercialization, with milestones intended to drive revenues and a $300 million EBITDA target for 2031.
ASP Isotopes hosts inaugural Capital Markets Day in London and says it is transitioning from development into early commercialization with milestones to drive revenues and a $300 million EBITDA target for 2031.Key Highlights:Original SEC Filing: ASP Isotopes Inc. [ ASPI ] - 8-K - Sep. 08, 2026This…